Ross D. Hannan

This paper identifies a synergistic combination of RNA Polymerase I inhibitor CX-5461 and CDK inhibitor Dinaciclib that enhances therapeutic efficacy in AML by inducing nucleolar stress and cell cycle arrest.

RICO quantifies rDNA copy number and methylation using nanopore sequencing, showing accurate results in simulations and human/mouse samples, and revealing correlations between rDNA CN and methylation.

The paper shows that CX-5461, a ribosome biogenesis inhibitor, increases platelet counts in humans and enhances megakaryopoiesis in mice without affecting platelet function or inflammatory cytokines.

This study shows PMR-116, a second-generation RiBi inhibitor, effectively targets high-MYC cancers without causing DNA damage, suggesting RiBi as a viable cancer therapy.

The paper introduces a method to estimate rDNA copy number using modal coverage and applies it to yeast isolates, finding population-level variation in copy numbers.

The paper introduces a method to quantify protein synthesis rates by analyzing ribosome co-localization dynamics on mRNA.

The paper introduces Sel-TCP-seq to study initiation factor dynamics, revealing staged initiation and co-translational assembly of initiation complexes in yeast and human cells.

This study identifies AGO1 as a tumour suppressor in Drosophila that represses Myc transcription, inhibiting cell and tissue growth through direct transcriptional repression.

The paper identifies Psi as a repressor of developmental pathways that promotes Drosophila wing growth by both activating Myc and repressing growth inhibitors.